Evidence map›Paper›PMID 37676002›Full record

ArticleJournal of virology2023

Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.

James Brett Case, Suzanne M Scheaffer, Tamarand L Darling, Traci L Bricker, Lucas J Adams, Houda H Harastani, Reed Trende, Shilpa Sanapala, Daved H Fremont, Adrianus C M Boon and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

James Brett Case *Department of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.ORCID 0000-0001-7331-5511
Suzanne M Scheaffer *Department of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Tamarand L DarlingDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Traci L BrickerDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Lucas J AdamsDepartment of Pathology & Immunology, Washington University School of Medicine , St. Louis, Missouri, USA.
Houda H HarastaniDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Reed TrendeDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Shilpa SanapalaDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.
Daved H FremontDepartment of Pathology & Immunology, Washington University School of Medicine , St. Louis, Missouri, USA.
Adrianus C M BoonDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.ORCID 0000-0002-4700-8224
Michael S DiamondDepartment of Medicine, Washington University School of Medicine , St. Louis, Missouri, USA.ORCID 0000-0002-8791-3165
Washington University in St. Louis · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
TO PROVIDE SCIENTIFIC SUPPORT TO THE CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES.75N93022C00035 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SATCHELL, KARLA · 2022 to 2025
$20.7M
COVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00062NIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93021C00016NIAID NIH HHS 75N93022C00035NIAID NIH HHS R01 AI157155
6 · The paper itself

Abstract

The continued evolution and emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have resulted in challenges to vaccine and antibody efficacy. The emergence of each new variant necessitates the need to re-evaluate and refine animal models used for countermeasure testing. Here, we tested a recently circulating SARS-CoV-2 Omicron lineage variant, BQ.1.1, in multiple rodent models including K18-human ACE2 (hACE2) transgenic, C57BL/6J, and 129S2 mice, and Syrian golden hamsters. In contrast to a previously dominant BA.5.5 Omicron variant, inoculation of K18-hACE2 mice with BQ.1.1 resulted in substantial weight loss, a characteristic seen in pre-Omicron variants. BQ.1.1 also replicated to higher levels in the lungs of K18-hACE2 mice and caused greater lung pathology than the BA.5.5 variant. However, in C57BL/6J mice, 129S2 mice, and Syrian hamsters, BQ.1.1 did not cause increased respiratory tract infection or disease compared to animals administered BA.5.5. Moreover, the rates of direct contact or airborne transmission in hamsters were not significantly different after BQ.1.1 and BA.5.5 infections. Taken together, these data suggest that the BQ.1.1 Omicron variant has increased virulence in rodent species that express hACE2, possibly due to the acquisition of unique spike mutations relative to earlier Omicron variants. IMPORTANCE As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, there is a need to rapidly assess the efficacy of vaccines and antiviral therapeutics against newly emergent variants. To do so, the commonly used animal models must also be re-evaluated. Here, we determined the pathogenicity of the BQ.1.1 SARS-CoV-2 variant in multiple SARS-CoV-2 animal models including transgenic mice expressing human ACE2 (hACE2), two strains of conventional laboratory mice, and Syrian hamsters. While BQ.1.1 and BA.5.5 infection resulted in similar levels of viral burden and clinical disease in hamsters and the conventional strains of laboratory mice tested, increases in lung infection were detected in hACE2-expressing transgenic mice, which corresponded with greater levels of pro-inflammatory cytokines and lung pathology. Taken together, our data highlight important differences in two closely related Omicron SARS-CoV-2 variant strains and provide a foundation for evaluating countermeasures.

Indexed as

COVID-19Disease Models, AnimalMesocricetusSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsCricetinaeHumansLungMiceMice, Inbred C57BLMice, TransgenicSpike Glycoprotein, CoronavirusViral LoadVirulenceACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BA.5.5BQ.1.1coronaviruspathogenesisSARS-CoV-2variants

Identifiers

PMID37676002
PMCPMC10537574
OpenAlexW4386498107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.